
Docs Who Lift
Docs Who LiftAudio
- Format:
- Podcast
- New episodes:
- Every two weeks
- Typical length:
- about 40 minutes
- Latest episode:
About this show
Drs. Spencer and Karl Nadolsky talk about nutrition, medicine, and fitness through the lens of two physicians who lift weights. Both doctors are former NCAA division 1 wrestlers who have gone into medicine. Dr. Spencer Nadolsky is a board certified family physician specialized in obesity medicine and lipidology. Dr. Karl Nadolsky is a board certified endocrinologist also specialized in obesity medicine.
Covers: nutrition, medicine, obesity medicine, fitness, glp-1 medications, weight loss drugs, peptides, menopause, endocrinology, bone health
Show details and episodes come from the publisher's public feed at feeds.simplecast.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
Docs Who Lift is a podcast where two physicians who lift weights discuss nutrition, medicine, and fitness. Recent episodes cover peptides like BPC-157, menopause misinformation, next-generation GLP-1 drugs, food noise, and renaming PCOS.
Cosmos
Similar in subject
- The Peptide Podcast
Both cover: peptides, bone health, glp-1 medications - Fat Science
Both cover: weight loss drugs, obesity medicine, glp-1 medications - Between Two Lips
Both cover: bone health, menopause, fitness
Similar shows
Explore more
Episodes
GLP-1 meds and macular degeneration
· 33 min
Learn what age-related macular degeneration (AMD) is What causes AMD The types of AMD The update on NAION - listen to last year's podcast all about it Why we aren't too concerned Click here to join Dr. Spencer's online clinic Vineyard Click to read the JAMA AMD article (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2834964) Click to read the Ophthalmology journal AMD article (https://pubmed.ncbi.nlm.nih.gov/39863057/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetMenopause, MHT, and GLP-1 medicines
· 27 min
- Menopausal hormonal therapy should not be a blanket recommendation for everyone going through menopause - Weight management in women is influenced by hormonal changes throughout life stages. - Retrospective analyses can provide insights but have limitations. - The wellness industry often oversimplifies complex medical issues. - Hormonal replacement therapy may have subtle benefits for weight management. - Confounding factors like SSRIs can complicate weight loss efforts. - A holistic approach is essential for managing women's health during menopause. - Education and awareness are crucial for women navigating menopause. - Future research should focus on randomized controlled trials for better clarity. - Understanding individual patient experiences is key to effective treatment. Click here to see her study (https://pubmed.ncbi.nlm.nih.gov/40074721/) Click here to follow Dr. Tchang on X (https://x.com/BevTchangMD) Click here to join Dr. Spencer's clinic Vineyard (https://joinvineyard.com/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetThe Science of Myostatin inhibitors, GLP-1 meds and Muscle Mass
· 28 min
- Dr. Grant Tinsley joins the discussion as the body composition expert. - Myostatin is a key regulator of muscle growth. - Wendy Whippete the most jacked muscled up dog (https://www.timescolonist.com/local-news/wendy-the-whippet-famed-for-massive-muscles-has-died-4645620) - The concern of GLP-1 receptor agonists and muscle mass loss. - Overview of Courage trial looking at semaglutide and trevogrumab and lean mass loss (https://newsroom.regeneron.com/news-releases/news-release-details/interim-results-ongoing-phase-2-courage-trial-confirm-potential) - Upcoming Believe trial coming out (bimagrumab and semaglutide) (https://www.adameetingnews.org/researchers-to-share-weight-loss-results-from-bimagrumab-and-semaglutide-combo/) - Exercise remains crucial for muscle health and function. - MRI data from SURPASS MRI provides new insights into muscle volume changes. (https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00027-0/fulltext) - The combination of medications may have varying effects on muscle mass. - Caution is advised regarding the long-term effects of new drugs. - Clinical benefits of medications often outweigh concerns about muscle loss. - Future research will explore the synergy between exercise and medication. Other docs who lift podcasts with Dr. Grant: Tirzepatide muscle loss (https://podcasts.apple.com/us/podcast/tirzepatide-and-muscle-loss-with-dr-grant-tinsley/id1611961208?i=1000696844484) Lean mass loss and GLP-1 meds (https://podcasts.apple.com/us/podcast/glp-1-agonists-and-lean-body-mass-loss-part-2-w-dr/id1611961208?i=1000610443673) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetCurrent State of Nutrition Research and MAHA
· 56 min
Takeaways: - The MAHA report aims to address public health issues but lacks actionable policies. - Historical context is crucial for understanding current dietary guidelines. - Funding for nutrition research has been inadequate, impacting the quality of data. - Public perception of nutrition often outpaces scientific evidence. - The evolution of dietary guidelines reflects political and social influences. - There is a need for more rigorous nutrition science to inform policy. - The dietary guidelines have not significantly improved population health metrics. - Political will is essential for implementing effective nutrition policies. - Nutrition science faces challenges in funding and research infrastructure. - The MAHA report's recommendations may be more performative than substantive. Food policy changes are often superficial and ineffective. - There is a significant disconnect between policy and actual health outcomes. - Nutrition science is underfunded and lacks high-quality research. - Misinformation in nutrition can lead to harmful public health outcomes. - The focus on food additives distracts from more pressing issues like obesity. - Experts are being sidelined in favor of political agendas. - Public trust in health recommendations has eroded post-COVID. - Nutrition policies need to be based on solid scientific evidence. - The food industry needs clearer guidance on reformulating products. - Future nutrition policies must prioritize public health over political gain Read Dr. Kevin's paper (https://pubmed.ncbi.nlm.nih.gov/40367956/) Follow Dr. Kevin on instagram (https://www.instagram.com/kcklatt/?hl=en) Join Dr. Spencer's clinic (https://joinvineyard.com/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetJoy Prescriptions
· 46 min
Click to read Joy Prescriptions (https://www.amazon.com/Joy-Prescriptions-Learned-Perfection-Connection/dp/0306834537) Drs. Karl and Spencer talk to Dr. Tiffany Moon all about Joy Prescriptions. Learn how to stop chasing perfection and embrace connection. 00:00Introduction to Dr. Tiffany Moon 02:02Journey to Reality TV: The Real Housewives of Dallas 05:58Life After Reality TV: Finding Joy and Purpose 09:59The Joy Prescription: A New Approach to Life 17:01Work-Life Integration: Balancing Career and Family 22:09Empowering Women: The Lead Her Summit 22:33Tiffany's Journey: From Childhood to Medical Success 24:43The Quest for Joy: Breaking the Hedonic Treadmill 26:42Finding Gratitude and Connection in Life 28:37Coping Mechanisms: Humor and Self-Reflection 29:57The Joy Prescription: A Path for High Achievers 32:29Reconstructing Identity: Beyond External Validation 35:37The Impact of Sports on Identity and Achievement 40:54Closing Thoughts: Embracing Joy and Connection Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetZepbound versus Wegovy
· 20 min
- Tirzepatide is more effective for weight loss than semaglutide. - Cost-effectiveness is crucial in prescribing weight loss medications. - Patients with severe obesity should receive more expensive medications for better outcomes. - Both medications show significant benefits for obesity-related conditions. - Long-term studies indicate sustained weight loss with both drugs. - Gender differences affect weight loss outcomes with these medications. - Safety profiles show tirzepatide may be better tolerated than semaglutide. - The need for affordable drug pricing is emphasized. - Clinical benefits extend beyond weight loss to include metabolic health. - Future studies are needed to confirm cardiovascular benefits of tirzepatide. Click here to see the study (https://www.nejm.org/doi/full/10.1056/NEJMoa2416394) Click here to join Dr. Spencer's new online clinic (https://joinvineyard.com/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetSemaglutide for metabolic dysfunction associated steatotic liver disease (MASH).
· 22 min
Takeaways - MASH is a significant obesity-related complication. - Semaglutide shows promise in treating MASH. - Weight loss is crucial for improving liver health. - Bariatric surgery remains the most effective treatment. - The Essence trial indicates a 63% resolution of NASH. - New medications are being developed for obesity treatment. - Early intervention is key to preventing severe liver damage. - Accessibility of medications is a major concern. - Comparative studies are essential for evaluating new treatments. - Future treatments may include innovative delivery methods. Chapters 00:00 Introduction to MASH and Semaglutide Study 04:29 Understanding Metabolic Dysfunction and Its Implications 08:02 Essence Trial: Semaglutide's Impact on MASH 12:58 Comparative Analysis of New Treatments for MASH 17:30 The Future of Obesity Treatment and Drug Accessibility Join Vineyard - Dr. Spencer's online clinic (https://joinvineyard.com/) See the study (https://www.nejm.org/doi/full/10.1056/NEJMoa2413258) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetTop 5 Women's Fitness Myths
· 36 min
Drs. Karl and Spencer chat with return guest Dr. Lauren Semple about creatine, protein, cortisol, fasting exercise, and training in women. Follow Dr. Lauren's instagram (https://www.instagram.com/drlaurencs1/) Join Dr. Spencer's online clinic (https://joinvineyard.com/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetGLP-1 and metabolism and depression
· 25 min
Drs. Karl and Spencer discuss a new study looking at tirzepatide and metabolic rate. They also discuss a patient case of tirzepatide induced anhedonia. Here is the tirzepatide study (https://www.cell.com/cell-metabolism/abstract/S1550-4131(25)00114-7) If interested in joining Dr. Spencer's clinic Vineyard - Click Here (https://joinvineyard.com/join/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yetDo GLP-1 meds cause more fat cells?
· 25 min
Drs. Karl and Spencer discuss the claim that GLP-1 meds cause more fat cells. Learn about if and how GLP-1 meds increase fat cells and what that means along with other claims about these medicine. Join Dr. Spencer's online clinic that specializes in GLP-1 medicines (https://joinvineyard.com/join/) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.
Not rated yet